WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , 

ISSN 2457-0400

Impact Factor  :  6.711

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • WJAHR: DECEMBER ISSUE PUBLISHED

    DECEMBER 2024 Issue has been successfully launched on DECEMBER 2024.

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR December 2024 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

Best Article Awards

World Journal of Advance Healthcare Research (WJAHR) is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

NUCLEAR MEDICINE AS MOLECULAR IMAGING PROBES RADIONUCLIDE IN RADIOPHARMACEUTICALS IN SCINTIGRAPHY OF DIAGNOSTIC AIDS

Amarnath De, Nilotpal Chandra Roy, Swapnamohan Goswami, Arkadyuti Sarkar, Pradip Guchait, Sovandip Brahma and Dhrubo Jyoti Sen*

ABSTRACT

Radiopharmaceuticals are a special class of drugs. They include diagnostic agents, such as molecular imaging probes, contrast agents or tracers, as well as agents that treat diseases, called radio therapeutics. A radiopharmaceutical contains a radioactive isotope that emits energy, which can be detected or used to provide an image (diagnostic agent) or is directly therapeutic within a diseased tissue. Millions of patients receive radiopharmaceuticals annually for a wide variety of medical procedures ranging from the assessment of cardiac function to staging and treatment of cancer. Diagnostic radiopharmaceuticals are administered to a patient and enable physicians and researchers to non-invasively see the biochemical activity of cells, to diagnose or stage disease, identify which patients are best suited for a particular treatment, and help monitor a patient’s response to treatment. The imaging probes selectively locate at the site of disease, and release positrons or gamma rays that can be detected and digitally imaged with specialized cameras, producing images through positron emission tomography (PET) or single photon emission computed tomography (SPECT). The probes accumulate at the site of disease and the images appear as colored or dark regions in partial or whole body structural images provided by computed tomography (CT) or magnetic resonance imaging (MRI). Community Preservation and Development Corporation (CPDC) currently markets and distributes diagnostic radiopharmaceuticals and is providing next generation imaging probes for our partners’ clinical trials. Therapeutic radiopharmaceuticals are administered to a patient to selectively seek out and deliver cell-killing radiation to the site of disease. These drugs are designed to bind selectively to specific biochemical protein receptors on or within cells at the site of the disease. Therapeutic radiopharmaceuticals can take many forms including highly selective proteins and antibodies, peptides or small molecules. The different types of molecules are designed to carry radioactive isotopes that release high energy α or β particles, which cause damage to the target cell’s DNA resulting in cell death. New therapeutic radiopharmaceuticals are being designed to precisely target and kill cancer cells, while sparing normal healthy tissue, and clearing rapidly from blood and tissues. The CPDC develops therapeutic radiopharmaceuticals for cancer and supplies radio therapeutics for clinical trials.

[Full Text Article] [Download Certificate]